[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Inc (PVLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,815,588
  • Shares Outstanding, K 14,314
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,720 K
  • EBIT $ -39 M
  • EBITDA $ -39 M
  • 60-Month Beta -0.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 54.28

Options Overview Details

View History
  • Implied Volatility 74.18% (+2.59%)
  • Historical Volatility 55.66%
  • IV Percentile 34%
  • IV Rank 4.18%
  • IV High 246.56% on 02/17/26
  • IV Low 66.67% on 12/18/25
  • Expected Move (DTE 10) 12.54 (9.82%)
  • Put/Call Vol Ratio 21.00
  • Today's Volume 88
  • Volume Avg (30-Day) 100
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 3,886
  • Open Int (30-Day) 4,431
  • Expected Range 115.07 to 140.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.89
  • Number of Estimates 4
  • High Estimate $-0.80
  • Low Estimate $-1.05
  • Prior Year $-0.74
  • Growth Rate Est. (year over year) -20.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.83 +13.10%
on 04/07/26
138.64 -7.96%
on 04/22/26
+4.15 (+3.36%)
since 04/02/26
3-Month
74.40 +71.52%
on 02/05/26
151.18 -15.59%
on 02/26/26
+45.60 (+55.60%)
since 02/04/26
52-Week
20.20 +531.73%
on 06/18/25
151.18 -15.59%
on 02/26/26
+103.15 (+421.71%)
since 05/02/25

Most Recent Stories

More News
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S. ...

PVLA : 127.61 (+0.61%)
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 127.61 (+0.61%)
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET WAYNE, Pa., April...

PVLA : 127.61 (+0.61%)
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership Author of a visionary 2015 Journal of...

PVLA : 127.61 (+0.61%)
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales...

INCY : 97.14 (+0.24%)
ARQT : 23.49 (+0.60%)
PVLA : 127.61 (+0.61%)
Palvella Therapeutics: Q4 Earnings Snapshot

Palvella Therapeutics: Q4 Earnings Snapshot

PVLA : 127.61 (+0.61%)
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026 Accelerating U.S....

PVLA : 127.61 (+0.61%)
Palvella's Rare Disease Bet Gets Its First Real Test—But Is Wall Street Even Asking the Right Questions?

Barchart Research What to Expect from PVLA Earnings PVLA Generated March 30, 2026 Current Price $110.66 EPS Estimate $-0.95 Consensus Rating Strong Buy Average Move 2.37% Palvella's Rare Disease Bet Gets...

PVLA : 127.61 (+0.61%)
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript...

PVLA : 127.61 (+0.61%)
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization,...

PVLA : 127.61 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

See More

Key Turning Points

3rd Resistance Point 144.69
2nd Resistance Point 137.34
1st Resistance Point 132.48
Last Price 127.61
1st Support Level 120.27
2nd Support Level 112.92
3rd Support Level 108.06

See More

52-Week High 151.18
Last Price 127.61
Fibonacci 61.8% 101.15
Fibonacci 50% 85.69
Fibonacci 38.2% 70.23
52-Week Low 20.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.